RxDoctor Payments Data

Travis Bowen, MD

Internal Medicine · Springdale, ARNPI 1467629790

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 68 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$301
  • Novo Nordisk$231
  • Corium, LLC$206
  • AbbVie$146
  • Amgen$132
  • Boston Scientific$63
  • plus $307 from 14 others

What the payments were for

  • Food & beverage$1,387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,387 in reported general payments places this provider in the 75th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$52,606
Medicare patients
354
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$17,321
EliquisApixaban25$16,778
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,608
BrilintaTicagrelor11$5,085
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$968
Ventolin HfaAlbuterol Sulfate11$620
Losartan Potassium40$458
Albuterol Sulfate HfaAlbuterol Sulfate23$456
Atorvastatin Calcium46$374
Gabapentin15$275
Omeprazole25$266
Oxycodone Hcl26$255
Tramadol Hcl44$242
Levothyroxine Sodium43$204
Tamsulosin Hcl20$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$231$17,32115 claims
PfizerEliquis$14$16,77825 claims
AstraZenecaBreztri Aerosphere, Brilinta$301$14,69326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →